Uploaded May 2022 | Updated November 2026, 8 hours ago
START-UP OF THE YEAR
CAMBIUM MEDICAL TECHNOLOGIES – PREPARATION AND USAGE OF HEPARIN- CONJUGATED FIBRINOGEN DEPLETED POOLED HUMAN PLATELET LYSATE FOR REGENERATIVE MEDICINE
EDMUND WALLER, MD, PHD; JOHN ROBACK, MD, PHD
Cambium Medical Technologies was founded in 2013 by four professionals from Emory University. They are focused on developing and commercializing regenerative therapeutics created from novel processed human platelets. Since the licensing of Emory technology “Preparation and Usage of Heparin- Conjugated Fibrinogen Depleted Pooled Human Platelet Lysate for Regenerative Medicine” in 2014, Cambium Medical Technologies has successfully completed a Phase I/II FDA dry eye clinical study for their product Elate Ocular®. In 2021, Cambium received approval from the FDA to begin two Phase III clinical trials for their dry eye biologic.
More information: https://www.ott.emory.edu/about/annual-celebrations/index.html
START-UP OF THE YEAR
CAMBIUM MEDICAL TECHNOLOGIES – PREPARATION AND USAGE OF HEPARIN- CONJUGATED FIBRINOGEN DEPLETED POOLED HUMAN PLATELET LYSATE FOR REGENERATIVE MEDICINE
EDMUND WALLER, MD, PHD; JOHN ROBACK, MD, PHD
Cambium Medical Technologies was founded in 2013 by four professionals from Emory University. They are focused on developing and commercializing regenerative therapeutics created from novel processed human platelets. Since the licensing of Emory technology “Preparation and Usage of Heparin- Conjugated Fibrinogen Depleted Pooled Human Platelet Lysate for Regenerative Medicine” in 2014, Cambium Medical Technologies has successfully completed a Phase I/II FDA dry eye clinical study for their product Elate Ocular®. In 2021, Cambium received approval from the FDA to begin two Phase III clinical trials for their dry eye biologic.
More information: https://www.ott.emory.edu/about/annual-celebrations/index.html










